{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:00:08Z","timestamp":1793260808693,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11748-025-02171-w","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:09:42Z","timestamp":1750126182000},"page":"641-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of trimetazidine on cardiac function and ventricular remodeling in patients with ischemic cardiomyopathy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"73","author":[{"given":"Wenjing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"6","key":"2171_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/FJC.0b013e31817bdd66","volume":"51","author":"R Belardinelli","year":"2008","unstructured":"Belardinelli R, Cianci G, Gigli M, et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol. 2008;51(6):611\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"2171_CR2","doi-asserted-by":"publisher","first-page":"602.e1","DOI":"10.1016\/j.ahj.2007.06.033","volume":"154","author":"P Di Napoli","year":"2007","unstructured":"Di Napoli P, Di Giovanni P, Gaeta MA, et al. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J. 2007;154(3):602.e1-5.","journal-title":"Am Heart J"},{"issue":"4","key":"2171_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","volume":"5","author":"T El-Kady","year":"2005","unstructured":"El-Kady T, El-Sabban K, Gabaly M, et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5(4):271\u20138.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"2171_CR4","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1016\/S0002-8703(03)00415-0","volume":"146","author":"G Fragasso","year":"2003","unstructured":"Fragasso G, Piatti Md PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146(5):E18.","journal-title":"Am Heart J"},{"issue":"4","key":"2171_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5582\/ddt.2022.01020","volume":"16","author":"RP Harjoko","year":"2022","unstructured":"Harjoko RP, Sobirin MA, Uddin I, et al. Trimetazidine improves left ventricular global longitudinal strain value in patients with heart failure with reduced ejection fraction due to ischemic heart disease. Drug Discov Ther. 2022;16(4):177\u201384.","journal-title":"Drug Discov Ther"},{"issue":"2","key":"2171_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00129784-200707020-00006","volume":"7","author":"A Labrou","year":"2007","unstructured":"Labrou A, Giannoglou G, Zioutas D, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs. 2007;7(2):143\u201350.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"2171_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ihj.2016.03.021","volume":"68","author":"A Momen","year":"2016","unstructured":"Momen A, Ali M, Karmakar PK, et al. Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy\u2014six months follow-up result. Indian Heart J. 2016;68(6):809\u201315.","journal-title":"Indian Heart J"},{"key":"2171_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1475-2840-2-16","volume":"2","author":"GM Rosano","year":"2003","unstructured":"Rosano GM, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003;2:16.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2171_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40261-014-0170-9","volume":"34","author":"X Xu","year":"2014","unstructured":"Xu X, Zhang W, Zhou Y, et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up. Clin Drug Investig. 2014;34(4):251\u20138.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2171_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ijcard.2014.10.149","volume":"177","author":"S Peng","year":"2014","unstructured":"Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177(3):780\u20135.","journal-title":"Int J Cardiol"},{"issue":"9","key":"2171_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137775","volume":"10","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Ma XJ, Shi DZ. Effect of trimetazidine in patients undergoing percutaneous coronary intervention: a meta-analysis. PLoS ONE. 2015;10(9): e0137775.","journal-title":"PLoS ONE"},{"issue":"6","key":"2171_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00059-015-4392-2","volume":"41","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Peng L, Luo Y, et al. Trimetazidine improves exercise tolerance in patients with ischemic heart disease: a meta-analysis. Herz. 2016;41(6):514\u201322.","journal-title":"Herz"},{"issue":"5","key":"2171_CR13","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.3892\/mmr.2016.5773","volume":"14","author":"N Ma","year":"2016","unstructured":"Ma N, Bai J, Zhang W, et al. Trimetazidine protects against cardiac ischemia\/reperfusion injury via effects on cardiac miRNA-21 expression, Akt and the Bcl-2\/Bax pathway. Mol Med Rep. 2016;14(5):4216\u201322.","journal-title":"Mol Med Rep"},{"issue":"6","key":"2171_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/FJC.0000000000000487","volume":"69","author":"Y Zhong","year":"2017","unstructured":"Zhong Y, Zhong P, He S, et al. Trimetazidine protects cardiomyocytes against hypoxia\/reoxygenation injury by promoting AMP-activated protein kinase-dependent autophagic flux. J Cardiovasc Pharmacol. 2017;69(6):389\u201397.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2171_CR15","doi-asserted-by":"crossref","unstructured":"Fan Q, Niu Z, Ma L. Meta-analysis of trimetazidine treatment for cardiomyopathy. Biosci Rep. 2018;38(3) BSR20171583.","DOI":"10.1042\/BSR20171583"},{"issue":"12","key":"2171_CR16","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1007\/s12325-022-02315-x","volume":"39","author":"Z Min","year":"2022","unstructured":"Min Z, Xuelu L, Ran Z, et al. Effectiveness of trimetazidine in patients with chronic heart failure stratified by the expression of soluble suppression of tumorigenicity-2 (sST2): a prospective cohort study. Adv Ther. 2022;39(12):5514\u201329.","journal-title":"Adv Ther"},{"issue":"4","key":"2171_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.31083\/j.rcm2204149","volume":"22","author":"C Zhao","year":"2021","unstructured":"Zhao C, Jin C, He X, et al. The efficacy of trimetazidine in non-ischemic heart failure patients: a meta-analysis of randomized controlled trials. Rev Cardiovasc Med. 2021;22(4):1451\u20139.","journal-title":"Rev Cardiovasc Med"},{"issue":"8","key":"2171_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00109-018-1664-3","volume":"96","author":"S Wu","year":"2018","unstructured":"Wu S, Chang G, Gao L, et al. Trimetazidine protects against myocardial ischemia\/reperfusion injury by inhibiting excessive autophagy. J Mol Med (Berl). 2018;96(8):791\u2013806.","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"2171_CR19","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1002\/ehf2.14418","volume":"10","author":"AA van de Bovenkamp","year":"2023","unstructured":"van de Bovenkamp AA, Geurkink KTJ, Oosterveer FTP, et al. Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial. ESC Heart Fail. 2023;10(5):2998\u20133010.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"2171_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/tox.23120","volume":"36","author":"BG Eid","year":"2021","unstructured":"Eid BG, El-Shitany NAE, Neamatallah T. Trimetazidine improved adriamycin-induced cardiomyopathy by downregulating TNF-\u03b1, BAX, and VEGF immunoexpression via an antioxidant mechanism. Environ Toxicol. 2021;36(6):1217\u201325.","journal-title":"Environ Toxicol"},{"key":"2171_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.630896","volume":"12","author":"K Wu","year":"2021","unstructured":"Wu K, Deng D, Yu B, et al. Evaluation of the efficacy and safety of Chinese herbal injection combined with trimetazidine for viral myocarditis: a network meta-analysis. Front Pharmacol. 2021;12: 630896.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2171_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14715\/cmb\/2021.67.2.11","volume":"67","author":"JM Maixent","year":"2021","unstructured":"Maixent JM, Pierre SV, Sadrin S, et al. Effects of long-term anti-ischemic drug treatment on Na, K-ATPase isoforms in cardiomyopathic hamsters. Cell Mol Biol (Noisy-le-grand). 2021;67(2):76\u201382.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"2","key":"2171_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00011-021-01530-6","volume":"71","author":"X Chen","year":"2022","unstructured":"Chen X, Lin S, Dai S, et al. Trimetazidine affects pyroptosis by targeting GSDMD in myocardial ischemia\/reperfusion injury. Inflamm Res. 2022;71(2):227\u201341.","journal-title":"Inflamm Res"},{"issue":"1","key":"2171_CR24","doi-asserted-by":"publisher","first-page":"25565","DOI":"10.31083\/FBL25565","volume":"30","author":"X Qu","year":"2025","unstructured":"Qu X, Yang P, Jiao L, et al. Trimetazidine: activating AMPK signal to ameliorate coronary microcirculation dysfunction after myocardial infarction. Front Biosci (Landmark Ed). 2025;30(1):25565.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2171_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118685","volume":"335","author":"L Lin","year":"2024","unstructured":"Lin L, Xu H, Yao Z, et al. Jin-Xin-Kang alleviates heart failure by mitigating mitochondrial dysfunction through the calcineurin\/dynamin-related protein 1 signaling pathway. J Ethnopharmacol. 2024;335: 118685.","journal-title":"J Ethnopharmacol"},{"key":"2171_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116479","volume":"229","author":"M Tan","year":"2024","unstructured":"Tan M, Yin Y, Chen W, et al. Trimetazidine attenuates ischemia\/reperfusion-induced myocardial ferroptosis by modulating the Sirt3\/Nrf2-GSH system and reducing oxidative\/nitrative stress. Biochem Pharmacol. 2024;229: 116479.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2171_CR27","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1097\/MJT.0000000000001430","volume":"28","author":"E Bobescu","year":"2021","unstructured":"Bobescu E, Marceanu LG, Dima L, et al. Trimetazidine therapy in coronary artery disease: the impact on oxidative stress, inflammation, endothelial dysfunction, and long-term prognosis. Am J Ther. 2021;28(5):e540\u20137.","journal-title":"Am J Ther"}],"container-title":["General Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-025-02171-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11748-025-02171-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-025-02171-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:07:24Z","timestamp":1757189244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11748-025-02171-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2171"],"URL":"https:\/\/doi.org\/10.1007\/s11748-025-02171-w","relation":{},"ISSN":["1863-6705","1863-6713"],"issn-type":[{"value":"1863-6705","type":"print"},{"value":"1863-6713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). As this study involves the summary and analysis of other studies, it does not involve medical ethics approval or patient-informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}